Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)

Abstract Plasmapheresis is a medical procedure that separates plasma from blood cells, potentially removing pro-aging factors from circulation. Some studies suggest it may have rejuvenating effects by altering biomarkers of aging, but evidence on its impact on epigenetic aging in humans is limited....

Full description

Saved in:
Bibliographic Details
Main Authors: Pavel Borsky, Drahomira Holmannova, Helena Parova, Steve Horvath, Petr Sramek, Robert T. Brooke, Milda Milciute, Juozas Gordevicius, Zdenek Fiala, Ctirad Andrys, Jan Kremlacek, Vit Rehacek, Ivana Baranova, Natalia Matyasovska, Lenka Borska
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-05396-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849238428146728960
author Pavel Borsky
Drahomira Holmannova
Helena Parova
Steve Horvath
Petr Sramek
Robert T. Brooke
Milda Milciute
Juozas Gordevicius
Zdenek Fiala
Ctirad Andrys
Jan Kremlacek
Vit Rehacek
Ivana Baranova
Natalia Matyasovska
Lenka Borska
author_facet Pavel Borsky
Drahomira Holmannova
Helena Parova
Steve Horvath
Petr Sramek
Robert T. Brooke
Milda Milciute
Juozas Gordevicius
Zdenek Fiala
Ctirad Andrys
Jan Kremlacek
Vit Rehacek
Ivana Baranova
Natalia Matyasovska
Lenka Borska
author_sort Pavel Borsky
collection DOAJ
description Abstract Plasmapheresis is a medical procedure that separates plasma from blood cells, potentially removing pro-aging factors from circulation. Some studies suggest it may have rejuvenating effects by altering biomarkers of aging, but evidence on its impact on epigenetic aging in humans is limited. This study aimed to assess whether plasmapheresis without volume replacement with young plasma or albumin affects epigenetic age and other biomarkers in healthy adults. An automatic plasma collection system, the Haemonetics PCS2, was used for plasmapheresis. Healthy blood donors were divided into two groups using stratified randomization in a cross-over study with subjects undergoing either 8 plasmaphereses (8 pp) or 4 plasmaphereses (4 pp) for an 18-week period, with a minimum interval between plasmaphereses of 2 weeks (14 days). Samples were tested for biochemical, hematological analyses and epigenetic clocks. We documented the alteration in serum minerals, decreased serum lipids, mainly total cholesterol, non-HDL, triglycerides, apolipoprotein A levels, total proteins and albumin. Among hematologic parameters, we found an increase in Red Cell Distribution Width (RDW) and Mean Corpuscular Hemoglobin Concentration (MCHC). No significant epigenetic rejuvenation was observed based on epigenetic clock measurements. Instead, plasmapheresis was associated with increases in DNAmGrimAge, the Hannum clock, and the Dunedin Pace of Aging. Plasmapheresis can rapidly change the levels of pro-inflammatory and other pro-aging molecules in the circulation. However, the selected protocol has not provided conclusive data supporting benefits. Based on epigenetic clock parameters, it may accelerate epigenetic aging. More research into the long-term safety of this specific protocol is needed.
format Article
id doaj-art-f30c5437c97e435cb542eeb4f9ea0680
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-f30c5437c97e435cb542eeb4f9ea06802025-08-20T04:01:36ZengNature PortfolioScientific Reports2045-23222025-07-0115111510.1038/s41598-025-05396-0Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)Pavel Borsky0Drahomira Holmannova1Helena Parova2Steve Horvath3Petr Sramek4Robert T. Brooke5Milda Milciute6Juozas Gordevicius7Zdenek Fiala8Ctirad Andrys9Jan Kremlacek10Vit Rehacek11Ivana Baranova12Natalia Matyasovska13Lenka Borska14Department of Preventive Medicine, Institute Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles UniversityDepartment of Preventive Medicine, Institute Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles UniversityDepartment of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles UniversityEpigenetic Clock Development FoundationHealthyLongevity.Clinic Inc.Epigenetic Clock Development FoundationEpigenetic Clock Development FoundationEpigenetic Clock Development FoundationDepartment of Preventive Medicine, Institute Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles UniversityDepartment of Clinical Immunology and Allergology, University Hospital and Faculty of Medicine in Hradec Kralove, Charles UniversityDepartment of Medical Biophysics, Faculty of Medicine in Hradec Kralove, Charles UniversityTransfusion Department, University Hospital Hradec KraloveDepartment of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles UniversityDepartment of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles UniversityDepartment of Preventive Medicine, Institute Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles UniversityAbstract Plasmapheresis is a medical procedure that separates plasma from blood cells, potentially removing pro-aging factors from circulation. Some studies suggest it may have rejuvenating effects by altering biomarkers of aging, but evidence on its impact on epigenetic aging in humans is limited. This study aimed to assess whether plasmapheresis without volume replacement with young plasma or albumin affects epigenetic age and other biomarkers in healthy adults. An automatic plasma collection system, the Haemonetics PCS2, was used for plasmapheresis. Healthy blood donors were divided into two groups using stratified randomization in a cross-over study with subjects undergoing either 8 plasmaphereses (8 pp) or 4 plasmaphereses (4 pp) for an 18-week period, with a minimum interval between plasmaphereses of 2 weeks (14 days). Samples were tested for biochemical, hematological analyses and epigenetic clocks. We documented the alteration in serum minerals, decreased serum lipids, mainly total cholesterol, non-HDL, triglycerides, apolipoprotein A levels, total proteins and albumin. Among hematologic parameters, we found an increase in Red Cell Distribution Width (RDW) and Mean Corpuscular Hemoglobin Concentration (MCHC). No significant epigenetic rejuvenation was observed based on epigenetic clock measurements. Instead, plasmapheresis was associated with increases in DNAmGrimAge, the Hannum clock, and the Dunedin Pace of Aging. Plasmapheresis can rapidly change the levels of pro-inflammatory and other pro-aging molecules in the circulation. However, the selected protocol has not provided conclusive data supporting benefits. Based on epigenetic clock parameters, it may accelerate epigenetic aging. More research into the long-term safety of this specific protocol is needed.https://doi.org/10.1038/s41598-025-05396-0PlasmapheresisAgingEpigenetic clockBiomarkers
spellingShingle Pavel Borsky
Drahomira Holmannova
Helena Parova
Steve Horvath
Petr Sramek
Robert T. Brooke
Milda Milciute
Juozas Gordevicius
Zdenek Fiala
Ctirad Andrys
Jan Kremlacek
Vit Rehacek
Ivana Baranova
Natalia Matyasovska
Lenka Borska
Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)
Scientific Reports
Plasmapheresis
Aging
Epigenetic clock
Biomarkers
title Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)
title_full Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)
title_fullStr Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)
title_full_unstemmed Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)
title_short Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)
title_sort human clinical trial of plasmapheresis effects on biomarkers of aging efficacy and safety trial
topic Plasmapheresis
Aging
Epigenetic clock
Biomarkers
url https://doi.org/10.1038/s41598-025-05396-0
work_keys_str_mv AT pavelborsky humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT drahomiraholmannova humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT helenaparova humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT stevehorvath humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT petrsramek humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT roberttbrooke humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT mildamilciute humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT juozasgordevicius humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT zdenekfiala humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT ctiradandrys humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT jankremlacek humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT vitrehacek humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT ivanabaranova humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT nataliamatyasovska humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial
AT lenkaborska humanclinicaltrialofplasmapheresiseffectsonbiomarkersofagingefficacyandsafetytrial